The hypothesis that WT KRAS, even when amplified, would predominantly be in the KRAS “OFF” state was assessed comparing the activity of two RAS “ON” inhibitors, RMC-6236 and RMC-7977, using published cell viability data (18, 39) derived from the same large cancer cell line panel (PRISM platform) used here to test BI-2493. The gene discussed is KRAS; the disease is cancer.